Gerresheimer stock forecast: Third-party price targets
Gerresheimer is a Germany-based manufacturer of pharmaceutical and healthcare packaging, listed in Europe and supplying containment and delivery solutions to global drugmakers. Explore third-party GXI price targets and technical analysis.
Gerresheimer AG (GXI) is trading around €25.15 in early European dealing on 4 February 2026, moving within an intraday range of €24.57–€25.37 on Capital.com’s CFD feed as of 1:17pm UTC. The price sits below late-January spot levels around €26–€27 on continental European venues. Past performance is not a reliable indicator of future results.
The move comes amid a broadly firmer German equity backdrop, with Germany’s main DE40 index up about 0.6% over the session and around 15% higher than a year earlier, pointing to comparatively resilient risk appetite in local equities (Trading Economics, 4 February 2026). Company-specific sentiment continues to reflect Gerresheimer’s October 2025 update, in which management adjusted 2025 guidance following slower market growth and announced a transformation programme (GlassOnline.com, 10 October 2025), alongside plans to separate and prepare a potential sale of its Moulded Glass division from 2026 (Packaging Journal,11 August 2025).
Gerresheimer stock forecast 2026–2030: Third-party price targets
As of 4 February 2026, third-party Gerresheimer stock predictions span from the low €20s to around the mid-€30s across recent broker notes and data-vendor updates, although some model-based and consensus feeds continue to reference higher historical targets from late 2025. The following items summarise selected third-party views, all carrying explicit capture or publication dates in early 2026.
Jefferies (broker rating update)
Jefferies maintains a Buy rating on Gerresheimer with a stated price target of €34.10 per share. The broker notes in its sector commentary that the company has fallen somewhat out of favour with investors, adding that this backdrop could leave room for positive surprises if fundamentals stabilise (Jefferies, 2 February 2026).
Yahoo Finance (analyst target snapshot)
Yahoo Finance lists an average 12-month GXI stock forecast of about €34.17, with a published low target around €22 and a high target near €45. The site states that these figures aggregate several covering analysts’ estimates for the XETRA-listed shares, reflecting ongoing adjustments to earnings forecasts and recommendations (Yahoo Finance, 3 February 2026).
Fintel (GXI) (monthly consensus level)
A monthly summary on Fintel for XETRA-listed Gerresheimer indicates an average one-year price target of €38.7, with a low forecast of €23.23 and a high forecast of €105. The service notes that these targets reflect where analysts consider the stock fairly valued relative to projected and historical earnings, with estimates compiled and refreshed on a monthly basis (Fintel, 21 January 2026).
TradingView (aggregated analyst target)
TradingView states that analysts’ one-year price target for GXI is around €31.30, with a maximum estimate of €46 and a minimum of €22. The platform explains that these values synthesise the views of 17 analysts over the prior three months, while noting that such opinions do not constitute trading advice (TradingView, 4 February 2026).
ValueInvesting.io (12-month forecast distribution)
ValueInvesting.io shows an average 12-month price target of €34.68 for GXI.DE based on 24 analysts, with a low target of €23.23 and a high of €105 as of 29 November 2024. The site notes that the consensus recommendation at that time was ‘BUY’ and that its dashboard combines historical and newer forecasts into a low-to-high distribution used for scenario analysis.
Predictions and third-party forecasts are inherently uncertain, as they cannot fully account for unexpected market developments. Past performance is not a reliable indicator of future results.
GXI stock price: Technical overview
The GXI stock price is trading around €25.15 on 4 February 2026 at 1:17pm UTC, below a tight cluster of short- and medium-term simple moving averages, with the 10-, 20-, 50-, 100- and 200-day SMAs near 26, 26, 26, 29 and 39 respectively. In this configuration, the near-term trend appears weak, as price holds below the moving-average band and the 10-day EMA around 25.7 also sits above spot. The 9-day Hull moving average near 24.9 marks the closest dynamic support just beneath the market. The 14-day RSI around 40.6 is in lower-neutral territory, and the ADX near 16.7 signals a modest, non-dominant trend, suggesting momentum is subdued rather than extended in either direction.
On the topside, initial resistance sits near 27.4 (R1), and a daily close above that level would bring the 29.6 R2 area back into focus as a subsequent reference zone. On pullbacks, initial support is located around the classic pivot at 26.1, while the S1 region near 23.9 represents the next downside reference on the classic framework. These levels are indicative only (TradingView, 4 February 2026).
This technical analysis is for informational purposes and does not constitute financial advice or a recommendation to buy or sell any instrument.
Gerresheimer share price history (2024–2026)
GXI’s stock price has experienced a pronounced swing over the past two years, moving from the low-€80s in early 2025 to the mid-€20s by early 2026. The stock closed at €79.92 on 12 February 2025, then pushed higher through a cluster of highs in March, peaking at €82.77 on 24 February and trading above €80 for much of that month as volatility remained elevated.
From April 2025, the picture changed. After closing at €69.56 on 1 April, the price declined through the second half of the year, with notable gaps lower around late September – from €36.50 on 24 September to €28.63 by 28 October – followed by another leg down from €35.38 on 30 September to €24.23 by 24 November. By year-end, the stock was trading in the high-€20s, and into 2026 it continued to edge lower, with prices at €27.85 on 2 January and €25.21 on 4 February 2026, leaving it roughly two-thirds below its February 2025 levels on a price-only basis.
Past performance is not a reliable indicator of future results.
Gerresheimer (GXI): Capital.com analyst view
Gerresheimer’s share price over the past two years has transitioned from levels above €80 to the mid-€20s by early February 2026, reflecting a substantial de-rating from prior peaks and a shift in how the market prices its earnings and growth profile. Such moves can indicate that earlier expectations were revised, that sector sentiment has cooled, or that valuation assumptions have changed, depending on how fundamentals and cash flows evolve. At the same time, recent consolidation around the mid-€20s suggests that both buyers and sellers remain active, leaving room for further repricing in either direction as new information becomes available.
From a drivers perspective, Gerresheimer operates at the intersection of healthcare, pharmaceuticals and industrial manufacturing, meaning earnings can be influenced by trends in drug demand, contract volumes, input costs and capital-spending cycles. Stronger volumes in pharma packaging or successful portfolio adjustments could support revenue and margin stability, while weaker order books, regulatory developments or execution risks linked to restructuring plans could weigh on profitability and, in turn, the share price. Broader equity-market conditions, interest rates and overall risk appetite also remain relevant, as changes in the macro backdrop can affect valuations even in the absence of company-specific news.
Capital.com’s client sentiment for Gerresheimer CFDs
As of 4 February 2026, Capital.com client positioning in Gerresheimer CFDs is heavily skewed toward long positions, with buyers accounting for 95.8% of open positions compared with 4.2% sellers. This reflects a strong long bias among current clients, although positioning data represents a snapshot in time and can change as market conditions and prices evolve.
Summary – Gerresheimer 2026
- Gerresheimer’s share price declined sharply through 2025, falling from above €80 in February to the mid-€20s by the end of the year.
- A significant leg lower followed in late September 2025, when prices dropped from the mid-€30s to the mid-€20s over the subsequent two months.
- By early 2026, the stock was consolidating in the €25–€28 range, with recent prices near €25.21 on 4 February 2026.
- Technical indicators show the price trading below key moving averages, with a lower-neutral RSI and modest trend strength, pointing to subdued momentum rather than a clear directional signal.
Past performance is not a reliable indicator of future results.
FAQ
Who owns the most Gerresheimer stock?
Gerresheimer has a diversified shareholder base that typically includes institutional investors, asset managers and pension funds, alongside private investors. Like many mid-cap European industrial and healthcare-related companies, ownership levels can change as funds rebalance or adjust sector exposure. Public filings and regulatory disclosures therefore offer snapshots rather than a fixed picture, meaning the identity of the largest shareholders can vary over time depending on market conditions, index inclusion and investor sentiment.
What is the five-year Gerresheimer share price forecast?
There is no single, definitive five-year GXI stock forecast. Most analyst estimates focus on shorter horizons, such as 12 months, and even these can differ widely. Longer-term outcomes are influenced by factors such as earnings growth, execution of strategic plans, demand trends in pharmaceutical packaging and broader market conditions. Any longer-range projections are inherently uncertain and are generally best viewed as illustrative scenarios rather than precise predictions.
Is Gerresheimer a good stock to buy?
Whether Gerresheimer is considered a ‘good’ stock depends on an individual’s objectives, time horizon and risk tolerance. Analysts and data providers point to both potential positives, such as exposure to healthcare packaging, and risks, including earnings variability and execution challenges. The share’s price history also reflects periods of pronounced volatility, which may not suit all investors. As a result, assessments typically involve weighing valuation, fundamentals and external conditions rather than relying on a single indicator.
Could Gerresheimer stock go up or down?
Yes, Gerresheimer’s share price can move in either direction. Like most equities, it responds to a mix of company-specific developments, sector trends and broader market forces. Changes in earnings expectations, guidance updates, macroeconomic conditions or shifts in investor risk appetite can all influence price movements. Historical price action shows that both sharp declines and phases of consolidation have occurred, underlining that outcomes are not one-sided.
Should I invest in Gerresheimer stock?
Deciding whether to invest in Gerresheimer is a personal decision that depends on financial circumstances, objectives and understanding of the risks involved. Equity investments can rise or fall in value, and past performance does not indicate future results. Some investors choose to consider diversification, time horizon and risk management alongside company fundamentals when forming a view. This information is for general market insight only and does not constitute investment advice.
Can I trade Gerresheimer CFDs on Capital.com?
Yes, you can trade Gerresheimer CFDs on Capital.com. Trading share CFDs lets you speculate on price movements without owning the underlying asset and to take long or short positions. However, contracts for difference (CFDs) are traded on margin, and leverage amplifies both profits and losses. You should ensure you understand how CFD trading works, assess your risk tolerance, and recognise that losses can occur quickly.